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experiment was then performed using the MIC methodology as described above. The growth/no 147 growth interface was then determined using the visual colour change of resazurin (blue) in to the 148 pink resorufin product and used to plot isobolograms and for the calculation of the fractional 149 inhibitory concentration (FIC) as a measure of the effects of combination therapies. 
Synergy assessment by Bacterial Time Kill Assays 157
To investigate any synergistic effects on the rate of killing, time-kill assays were performed with 158 HT61 and tobramycin as previously described (22, 23) . Bacteria (5x10 5 cfu/mL) were cultured in 10 159 mL of CAMHB in glass flasks in the presence of tobramycin and/or HT61 at sub-inhibitory 160 concentrations. Cultures were incubated at 37°C for 24 hours under continuous shaking conditions 161 (130 rpm). Bacterial viability was determined by collecting aliquots at 0, 4, 8, 12 and 24 hours.
162
Samples of bacterial suspensions were then serially diluted in sterile saline and plated on TSA. Plates 163 were subsequently incubated at 37°C for 16-18 hours, and colony forming units counted.
165

Minimum biofilm concentration eradication assay 166
Effect of combination therapy was studies on biofilms by using the Calgary devices as previously 167 described with minor modifications (24). One colony was inoculated in CAMH and incubated (37°C, 168 130 rpm). After approximately 20 hours, cells were washed twice by centrifugation (5,000g, 4°c) and resuspension in sterile 0.9% NaCl. Bacterial suspensions were diluted to 10 5 cfu/mL in CAMH and 170 inoculated in a 96 well plate (150 μL per wells). Plate lids were replaced with the Nunc-TSP 96 Pin lid 171 and biofilms were left to form for 18-20 hours under shaking (110 rpm) in a wet atmosphere.
172
Established biofilms on pins were washed with 200 μL of sterile 0.9% NaCl and transferred into a 
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Bacterial embedded agar beads were prepared using the protocol described previously (25). Briefly, 189 bacterial cultures were prepared by inoculating a TSA plate with a stock cryobead and incubating at 190 37⁰C for 24 hours under static conditions. 24 hours prior to use, secondary overnight cultures were 191 prepared by inoculating 20ml of TSB with 2-3 bacterial colonies and subsequently incubated at 37⁰C 192 for 16 hours under rotary conditions of 120rpm. Bacteria were embedded into agar beads by mixing 193 the secondary overnight culture with molten TSA at a 1:9 ratio, which was then spun into mineral oil, previously heated to 50 o C. The preparation was cooled and centrifuged at 2700 g and the remaining 195 mineral oil was removed by washing with sterile PBS. Bacterial content of the beads was then 196 quantified on TSA plates and diluted to achieve 2x10 7 cfu/mL using sterile PBS, to deliver a final dose 197 of 1x10 6 cfu/mouse.
198
Animals were housed in filter top cages under standard conditions of 22±2⁰C with a 12:12 light: dark 199 cycle. All animals were provided with food and water ad libitum, and wood shavings, shredded paper 200 and cardboard tubes were provided for environmental enrichment. All animals were provided with a 201 minimum acclimatization period of 7 days upon arrival before the commencement of the study. 
Differences in MIC values for HT61 and tobramycin for strains of P. aeruginosa 230
The MICs of HT61 and Tobramycin were determined against 3 different strains of P. aeruginosa with 231 different susceptibility profiles to Tobramcyin. MICs values of HT61 ranged between 50 and 232 100µg/ml against each of the 3 strains (PA01: 100 µg/ml; NN2: 100 µg/ml; RP73: 50 µg/ml, Table 1 ).
233
Previous research has reported differential sensitivity of these 3 P.aeruginosa strains to Tobramycin, 234 with PA01 reported as a tobramycin sensitive strain, RP73 reported as a multidrug resistant strain 235 and NN2 reported as Tobramycin resistant (15). In our studies, in agreement with the previously 236 reported susceptibility profiles, we also reported marked differences in the MIC values of 237 Tobramycin to each of these strains with a range of 0.4-100µg/ml (PA01: 0.4 µg/ml; RP73: 3 µg/ml; 238 NN2: 100 µg/ml, Table 1 ). HT61 was more effective as demonstrated by the smaller MIC in CAMH in 239 comparison to LB and TSB for all three strains. Similarly, an enhanced susceptibility to tobramycin 240 was also observed in CAMH for strains PAO1 and RP73. 241 242 243
Chequerboard analysis revealed HT61 and tobramycin synergy against P. aeruginosa 244 strains RP73 and NN2 245
We have previously reported that HT61, demonstrated synergism against gram-positive bacteria in 246 vitro when used in combination with a number of aminoglycoside antibiotics, including neomycin, 247 gentamicin and mupirocin (10). We therefore extended this work by assessing the combined 264 aeruginosa cells (growth to approximately 10^10 CFU/mL for all strains examined). Assays that 265 combined both agents at the same concentration are shown as black triangles. Synergy was 266 subsequently defined as when the difference in bacteriasl numbers exceeded two log orders, when 267 comparing a combination of agents to single agents. Strong evidence for synergy was identified after 268 eight hours for strain PAO1 (Fig 2A) , with no cfu's detected for PA01 after 12 hours following 269 combination treatment of HT61 and Tobramycin in comparison to 10 8 cfu/ml following HT61 270 monotherapy and 10 4 cfu/ml following Tobramycin monotherapy at the same timepoint.
271
For strain RP73 (Fig 2B) , no difference between HT61 and Tobramycin monotherapies were 
HT61 significantly enhances tobramycin mediated biofilm eradication 282
Since P. aeruginosa infections are typically associated with bacteria persisting as biofilms, the impact 283 of combinations of HT61 and tobramycin was also investigated on these structured forms of growth.
284
Firstly, we investigated whether biofilm establishment in vitro was affected by singular treatment 285 with either HT61 or tobramycin through the checkerboard assay system. In our studies we observed 286 similar FICs values similar to those obtained from produced in the non-biofilm grown samples(data 287 not shown).
Secondly, we aimed to investigate the effect of tobramycin and HT61 on already established 289 biofilms. Biofilms, formed in inhibitor free conditions, were challenged with tobramycin and HT61.
290
The period of recovery required was used to determine the minimum biofilm eradication 291 concentration (MBEC). HT61 given as a monotherapy had no impact on bacterial cell numbers in 292 previously established biofilm structures (data not shown). As such, the impact of different 293 concentrations of tobramycin in the presence of fixed levels of HT61 (25, 50 or 100 μg/mL) was 294 assessed (Fig 3) . For all strains tested, the addition of HT61 significantly enhanced the ability of 295 tobramycin to eradicate biofilm located cells, as shown by the decreased MBEC. For strain PAO1 (Fig   296   3A) , the lowest concentration of tobramycin required to eradicate biofilms was 43.75 ± 4.49 μg/mL.
297
The addition of 25, 50 or 100 μg/mL of HT61 significantly reduced this MBEC to 26.56 ± 4.49 μg/mL 298 (p<0.05), 15.89 ± 2.48 μg/mL and 15.36 ± 2.59 μg/mL respectively (p<0.0001). For strain NN2 (Fig   299   3B ), MBEC for tobramycin alone was above 25 g/L. As the solubility limit was reached, tobramycin 300 MBEC was assumed to be 50 g/L for those replicates. The tobramycin MBEC alone was therefore 301 estimated at 43.75 ± 3.26 g/L, which was significantly reduced (p<0.0001) by at least 4-fold when 302 HT61 was added (10.94 ± 1.56 g/L, 9.90 ± 1.14 g/L, 6.77 ± 0.85 g/L). The strongest level of 303 enhancement on biofilm eradication was observed with RP73 (Fig 3C) . When used as a single agent, 304 200 μg/mL tobramycin was required to eradicate RP73 biofilm structures, whilst HT61 at 25, 50 or 305 100 μg/mL was shown to lower the tobramycin MBEC to 53.75 ± 10.87 μg/mL (3.7 fold), 33.13 ± 6.91 306 μg/mL (6-fold) and 25.0 ± 6.04 μg/mL (8-fold) respectively. 307 308
HT61 showed no bactericidal activity against any tested bacterial strain in vivo 309
The in vitro data described in sections 3.1-3.4 described an ability of HT61 to enhance the activity of 310 tobramycin against both RP73 and NN2. We therefore investigated whether this enhancement was 311 replicated in in vivo studies using a murine model of pulmonary infection with P. aeruginosa. Dose-312 response titrations of HT61 were performed towards infections with all three strains of P. aeruginosa described above, in order to determine whether HT61 monotherapy demonstrated any 314 bactericidal activity in vivo. In all studies, inoculation with 1x10 6 cfu RP73/NN2/PA01 per mouse 315 resulted in significant increases in bacterial cell numbers when compared to sham controls (Sham: 316 0.00 ± 0.00 log cfu/ml vs. RP73: 6.16 ± 0.22 log cfu/ml, P < 0.001; NN2: 4.85 ± 0.18 log cfu/ml, P < 317 0.001; PA01: 5.90 ± 0.03 log cfu/ml, P < 0.001, Figs 4A-C) . Single systemic treatment with 0.1, 1 and 318 5mg/kg HT61 i.p. failed to demonstrate any reduction in pulmonary bacterial load when compared 319 to vehicle treated controls at 48 hours against any of the three P. aeruginosa strains tested; RP73 320 (Vehicle: 6.16 ± 0.22 log cfu/ml vs 0.1mg/kg: 5.91 ± 0.12 log cfu/ml; 1mg/kg: 6.45 ± 0.12 log cfu/ml; 321 5mg/kg: 6.64 ± 0.41 log cfu/ml), NN2 (Vehicle: 4.85 ± 0.18 log cfu/ml vs 0.1mg/kg: 5.34 ± 0.32 log 322 cfu/ml; 1mg/kg: 5.12 ± 0.43 log cfu/ml; 5mg/kg: 5.80 ± 0.69 log cfu/ml) or PA01 (Vehicle: 5.90 ± 323 00.03 log cfu/ml vs 0.1mg/kg: 6.73 ± 0.20 log cfu/ml; 1mg/kg: 5.74 ± 0.14 log cfu/ml; 5mg/kg: 5.74 ± 324 0.33 log cfu/ml). This suggested that unlike in previous studies performed against gram-positive 325 bacteria, HT61 has no direct anti-bacterial activity against gram-negative P.aeruginosa. 326 327 3.6. HT61 significantly enhanced the efficacy of tobramycin against the P. aeruginosa 328
strains RP73, NN2 and PA01 in vivo 329
Our in vitro experiments demonstrated clear synergy between HT61 and tobramycin when used as a 330 combination therapy against P. aeruginosa strains RP73 and NN2, but not PA01. We therefore 331 subsequently assessed whether this in vitro finding could be translated in vivo using a murine model Figure 1) . From these experiments, 100mg/kg systemic tobramycin was selected for the drug resistant P. aeruginosa strains RP73 and NN2, whilst 50mg/kg was selected for P. aeruginosa reference strain PA01.
338
In the first series of the combination studies, mice were concomitantly treated with subthreshold 339 tobramycin doses as previously identified and 1mg/kg HT61. Supporting our earlier in vitro and in 340 vivo experiments described above, treatment with 1mg/kg HT61 alone demonstrated no reduction 341 in bacterial numbers 48 hours post treatment when compared to vehicle for RP73 (Vehicle: 5.54 ± 342 0.01 log cfu/ml vs 1mg/kg HT61: 5.65 ± 0.01 log cfu/ml), NN2 (Vehicle: 6.59 ± 0.21 log cfu/ml vs 343 1mg/kg HT61: 6.54 ± 0.20 log cfu/ml) or PA01 (Vehicle: 4.70 ± 0.13 log cfu/ml vs 1mg/kg HT61: 4.97 344 ± 0.06 log cfu/ml). Furthermore, monotherapy with the subthreshold dose of Tobramycin had no 345 effect on bacterial numbers when compared to vehicle for RP73 (Vehicle: 5.54 ± 0.01 log cfu/ml vs 346 100mg/kg tobramycin: 5.56 ± 0.01 log cfu/ml), NN2 (Vehicle: 6.59 ± 0.21 log cfu/ml vs 100mg/kg 347 tobramycin: 6.24 ± 0.24 log cfu/ml) or PA01 (Vehicle: 4.70 ± 0.13 log cfu/ml vs 50mg/kg Tobramycin: 348 5.06 ± 0.11 log cfu/ml) (Fig 5A and B) . However, when mice were treated with a combination of both 349 1mg/kg HT61 and tobramycin, a significant reduction in bacterial numbers was observed against the 350 multi-drug resistant strain RP73 (Vehicle: 5.54 ± 0.01 log cfu/ml vs 1mg/kg HT61 + 100mg/kg 351 Tobramycin: 4.51 ± 0.12 log cfu/ml, P < 0.001) and the tobramycin resistant strain NN2 (Vehicle: 6.59 352 ± 0.21 log cfu/ml vs 1mg/kg HT61 + 100mg/kg tobramycin: 5.49 ± 0.33 log cfu/ml, P < 0.05). In 353 contrast, this finding was not observed for the tobramycin sensitive strain PA01 (Vehicle: 4.70 ± 0.13 354 log cfu/ml vs 1mg/kg HT61 + 50mg/kg tobramycin: 5.00 ± 0.06 log cfu/ml) (Fig 5C) 
355
Next, we investigated whether the inability of HT61 to potentiate the activity of tobramycin against 356 PA01 was due to an insufficient dose of HT61 used in the combination treatments. We therefore 357 replicated the above studies using an increased 10mg/kg HT61 in the combination treatment with 
364
We were interested as to whether or not the significant reductions observed in vivo by combining 365 HT61 with tobramycin was due to an additive effect or due to synergistic interactions between the 366 two drugs. We therefore calculated the expected reductions in bacterial numbers if it were due to 367 an additive effect (Supplementary Table 2) . Here, the reductions in bacterial numbers observed for 368 all 3 strains suggested the possibility that a greater than additive effect was observed between HT61 369 and tobramycin, which supported our in vitro data.
371
Discussion
372
The properties of compounds such as HT61 have been of growing interest in terms of clinical utility.
373
In this study, we found that HT61 had little or no discernable antibacterial activity against the gram-374 negative pathogen P. aeruginosa in contrast to the previously described activity observed against 375 gram-positive bacteria (11). However, the key findings of this study were the identification of 376 significant synergistic activities between HT61 and the classical aminoglycoside antibiotic tobramycin 377 against P. aeruginosa. These findings have a particular bearing in terms of the clinical management 
382
In this study, 3 different strains of P. aeruginosa were considered including the multi-drug resistant 383 (RP73) and tobramycin resistant (NN2) strains (15) alongside PAO1 as a reference laboratory strain.
As such, these strains represented a range of known phenotypic responses to tobramycin. The 385 observation that HT61 in combination with tobramycin produced a synergistic effect in vitro against 386 the strains considered as resistant to tobramycin was therefore encouraging. In turn, this provided a 387 strong rationale for the assessment of the antibacterial activity of combinations of HT61 and 
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Given the concern over the lack of novel antibiotics in the pipeline, alternate strategies designed to 404 maximise and enhance the activity and in turn longevity of existing antibiotics are important.
405
Borrowing the same terminology as for antibiotic susceptibility, enhancers could either be narrow or 406 broad in their spectrum. The ability of HT61 therefore to render RP73, a nearly tobramycin resistant 407 strain (MIC of 3µg/mL), susceptible to tobramycin therapy (MIC reduced to 0.6µg/mL), both in vitro 408 and in vivo is therefore highly important. Such enhancer strategies would avoid scenarios whereby 409 resistance to an antibiotic is overcome by simply increasing the dose of the antibiotic prescribed. This is of particular relevance for aminoglycosides such as tobramycin, as it is neither feasible or 411 ethical to significantly increase the doses used due to their systemic toxicity profiles, as in addition 412 to their ototoxic and nephrotoxic side effects, chronic kidney disease has also been associated 413 chronic tobramycin treatment, in individuals with cystic fibrosis (29-32). As an alternative to simply 414 increasing antibiotic plasma levels, the use of multiple antibiotics in combination has been proposed 415 as a strategy capable of slowing the emergence of antimicrobial resistance whilst also shortening the 
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The resulting disruption of both membranes would increase the permeability of the gram-negative 442 bacterial membranes to tobramycin, resulting in an elevated intracellular tobramycin concentration 443 enhancing the bactericidal activity through its effects on protein synthesis (10,11). Whilst the 444 mechanism of action of HT61 remains open for discussion and further studies are required to fully 445 understand the mechanism of action of HT61 in the potentiation of tobramycin against gram-446 negative bacteria, it is also important to consider the impact on the mode of growth of P. 
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These studies therefore demonstrate an exciting enhancement of tobramycin's activity; however, 452 we acknowledge that our studies used an extended range of assays, the findings are limited by the 453 assessment of a single antibiotic. Whilst we used three individual strains of P. aeruginosa covering a 454 range in susceptibility to a tobramycin the assessment of HT61's ability to enhance the bactericidal 455 activity of additional antibiotics would further strengthen the findings detailed in this study.
456
In conclusion, the combination of tobramycin with HT61 demonstrated significant potentiation of 
